Vigafyde
Vigafyde is a brand-name antiepileptic medication containing vigabatrin as its active ingredient. It is primarily prescribed for the treatment of infantile spasms and as adjunctive therapy for refractory complex partial seizures in patients who have not responded adequately to other treatments. This medication requires careful monitoring due to the risk of serious visual field defects associated with its use.
Vigafyde is a prescription antiepileptic drug used to treat infantile spasms and certain refractory seizures, requiring regular vision monitoring during treatment.
Key facts at a glance
- RxNorm
- 2685218
- Generic
- Vigafyde
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vigafyde is used for the treatment of infantile spasms (West syndrome) in infants and children, and as adjunctive (add-on) therapy for adults with refractory complex partial seizures who have not responded sufficiently to other antiepileptic medications.
Vigafyde contains vigabatrin, which acts as an irreversible inhibitor of GABA transaminase, the enzyme responsible for breaking down GABA (gamma-aminobutyric acid). By inhibiting this enzyme, Vigafyde increases GABA levels in the brain, producing an anticonvulsant effect that helps reduce seizure activity.
Vigafyde carries a black box warning for the risk of permanent vision loss, including peripheral visual field defects. Regular ophthalmologic examinations are required before, during, and after treatment. The medication should only be used when the clinical benefits outweigh the risks of vision loss. Abrupt discontinuation should be avoided, and dosage adjustments must be made gradually under medical supervision.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy